Trial Profile

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atirmociclib (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary) ; PF-07248144 (Primary) ; Vepdegestrant (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms KAT6
Sponsors Pfizer

13 Aug 2025 Planned End Date changed from 30 Jan 2028 to 22 Sep 2029.
13 Aug 2025 Planned primary completion date changed from 30 Jan 2028 to 3 Feb 2028.
04 Jun 2025 Study phase changed from phase 1 to phase 1/2. Number of treatment arms have been increased from 8 to 10 by the addition of 2 new vepdegestrant combination experimental arms.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com